A targeted therapeutic approach could effectively treat chronic low back pain (cLBP), data suggests. The Phase Ib trial of PP353, developed by biotechnology company Persica Pharmaceuticals, demonstrated a clinically meaningful and durable reduction in pain and disability in patients with chronic low back pain and Modic Type 1 changes. Results have… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Steve Ruston, CEO… Read More
Persica Pharmaceuticals has announced positive topline data from its Phase Ib Modic Trial for PP353, a drug candidate with the potential to offer patients an alternative to long-term opioid use for pain relief by targeting the cause of the pain rather than the symptoms. The trial is… Read More
